Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults

• Egile Nagusiak: Goran Stevanovic (Egilea), Lidija Lavadinovic (Egilea), Svetlana Filipovic Vignjevic (Egilea), Renée Holt (Egilea), Katarina Ilic (Egilea), Francesco Berlanda Scorza (Egilea), Erin Sparrow (Egilea), Vera Stoiljkovic (Egilea), Guido Torelli (Egilea), Tamra Madenwald (Egilea), Muriel Socquet (Egilea), Aleksandra Barac (Egilea), Yordanka Ilieva-Borisova (Egilea), Mijomir Pelemis (Egilea), Jorge Flores (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2018-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The vaccine was manufactured in eggs by the Torlak Institute of Virology, Vaccines an...